Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31


α4-integrin receptor desaturation and disease activity return after natalizumab cessation.

Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A, Zhang Y, Wiendl H, Tomic D.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 25;4(5):e388. doi: 10.1212/NXI.0000000000000388. eCollection 2017 Sep.


Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.

Voigt D, Scheidt U, Derfuss T, Brück W, Junker A.

Int J Mol Sci. 2017 Apr 4;18(4). pii: E760. doi: 10.3390/ijms18040760.


Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.


Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R.

Dtsch Arztebl Int. 2016 Dec 26;113(51-52):879-886. doi: 10.3238/arztebl.2016.0879.


Cocapture of cognate and bystander antigens can activate autoreactive B cells.

Sanderson NS, Zimmermann M, Eilinger L, Gubser C, Schaeren-Wiemers N, Lindberg RL, Dougan SK, Ploegh HL, Kappos L, Derfuss T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):734-739. doi: 10.1073/pnas.1614472114. Epub 2017 Jan 5.


Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Derfuss T, Ontaneda D, Nicholas J, Meng X, Hawker K.

Mult Scler Relat Disord. 2016 Jul;8:124-30. doi: 10.1016/j.msard.2016.05.015. Epub 2016 May 24.


Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.

Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun.


The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.


Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.

Rust H, Kuhle J, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e215. doi: 10.1212/NXI.0000000000000215. eCollection 2016 Apr. No abstract available.


Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Rasenack M, Rychen J, Andelova M, Naegelin Y, Stippich C, Kappos L, Lindberg RL, Sprenger T, Derfuss T.

PLoS One. 2016 Jan 6;11(1):e0146190. doi: 10.1371/journal.pone.0146190. eCollection 2016.


Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.

J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. Review.


Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Wuhrer M, Selman MH, McDonnell LA, Kümpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M.

J Neuroinflammation. 2015 Dec 18;12:235. doi: 10.1186/s12974-015-0450-1.


Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.

Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e144. doi: 10.1212/NXI.0000000000000144. eCollection 2015 Oct.


B Cells and Autoantibodies in Multiple Sclerosis.

Pröbstel AK, Sanderson NS, Derfuss T.

Int J Mol Sci. 2015 Jul 21;16(7):16576-92. doi: 10.3390/ijms160716576. Review.


Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.


Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T.

J Neuroinflammation. 2015 Mar 8;12:46. doi: 10.1186/s12974-015-0256-1.


Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients.

Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, Mäurer M, Derfuss T.

PLoS One. 2014 Dec 31;9(12):e115488. doi: 10.1371/journal.pone.0115488. eCollection 2014.


Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

J Immunol Res. 2014;2014:897249. doi: 10.1155/2014/897249. Epub 2014 May 12.


Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.

Weier K, Penner IK, Magon S, Amann M, Naegelin Y, Andelova M, Derfuss T, Stippich C, Radue EW, Kappos L, Sprenger T.

PLoS One. 2014 Jan 22;9(1):e86916. doi: 10.1371/journal.pone.0086916. eCollection 2014.


Neurofascin as a target for autoantibodies in peripheral neuropathies.

Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, Linington C, Odaka M, Tackenberg B, Prüss H, Schwab JM, Harms L, Harms H, Sommer C, Rasband MN, Eshed-Eisenbach Y, Peles E, Hohlfeld R, Yuki N, Dornmair K, Meinl E.

Neurology. 2012 Dec 4;79(23):2241-8. doi: 10.1212/WNL.0b013e31827689ad. Epub 2012 Oct 24.

Supplemental Content

Loading ...
Support Center